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In the past few years, researches in the lysozyme have greatly extended. 
_t, is well known that the lysozyme is contained in the serum, in the urine —. 
in insignificant quantities, as well as in neutrophil granulocytes and mono-
cytes of the peripheral blood of healthy persons. Among bone marrow ele-
ments, lysozyme has been established in promyelocytes, and in the rather ma-
ture white blood cells (1 , 5). 
Changes in this particular enzyme in the serum and urine of leukosis pa-
tients have been subjected to a comparatively more detailed study. In the l i -
terature the opinions are unanimous in terms of the lysozyme increase in pa-
tients with monocytoid type of acute leukosis and chronic myelogenic leu-
kosis where it is considered that changes in lysozyme have both diagnostic 
and prognostic value (2, 3, 4, 5, 7, 9). There are no literature reports in this 
country concerning lysozyme studies in malignant hemopathies. 
The purpose of the present work is to try to find changes in muramidase 
in the serum and urine of patients with various systemic blood affections, as-' 
well as to determine their dependence on the type and stage of disease, and 
the effect of the treatment performed. 
Material and methods 
The study is conducted on a series of 76 clinically affected cases of which 
43 with leukosis diseases (acute leukosis, chronic myelogenic leukosis and 
chronic lymphatic leukosis), 20 with malignant lymphoblastoma, and 13 with 
other hemopathies (polycythemia vera, reticulosis). Forty seven practically 
healthy individuals were studied for control purposes. 
Quantitative lysozyme determination in the serum and urine was 
made after the method of Osserman and Lawlor, as modified by Zucker (8, 10). 
To about 100 ml 1 per cent agar (Difco) in 0.067 M sodium phosphate buffer 
(p-H 6.2), thawed and cooled to 60° C, 60 mg Micrococcus lysodeicticus from 
a 24-hour agar culture was added. Following mixture, a determined quantity 
was decanted in petri dishes at 4 mm thickness of the layer. Using a needle 
with 3 mm diameter, small wells were formed in the agar, and filled with 
the material under study by means of a Pasteur's pipette. The batches were 
kept at room temperature for a duration of 24 hours, and thereafter the dia-
meter of the zones lysed by the enzyme was measured. Readings of the lyso-
zyme in mcg/ml were made after the semilogarithmic curve, built on the basis 
of data from standard dilutions of egg lysozyme because of the lack of a hu 
man one. Lysozyme activity recordings in mcg/ml egg lysozyme have been 
described in the literature. (9). 
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Results and discussion 
The patients under study are 20 to 70 years old, including 50 males and 
26 females. The subjects in the control group are of both sexes and of compar­
able ages. 
Summed up data from the 
study on lysozyme activity are 
presented in Diagram 1. It shoSvs 
that the mean lysozyme values in the 
serum of the control group subjects 
amounts to 221.8 + 24.4 mcg/ml (single 
values ranging from 50 to 500), and 
in the urine — 2.33± 1.02 mcg/ml 
(single values ranging from 0 to 50). 
The group of leukosis diseases 
includes 13 patients with acute leu­
kosis, of which seven with lymphocy-
toid morphological type, five with 
mixed type, and only one with myelo­
blast type. The mean value of serum 
lysozyme in al l the patients of this 
group amounts to 174.9±46.3 mcg/ml 
which points to the fact that the en­
zyme activity remains inaltered as 
compared to that of the control group 
(P<0 .05) . In the urine as well no chan­
ges in the activity of the lysozyme 
were established in this particular 
group ( P < 0.05). 
In patients with acute leukosis, the specific data about lysozyme acti­
vity in the serum and urine show no increase; on the contrary, in three of them 
it is below the norm (20 mcg/ml). The latter had low leukocyte values. Essen­
tial variations of lysozyme activity were neither found in the various stages 
of the disease, namely before, during and after the treatment. I t is evident 
from the dynamic follow up study of seven patients that only in two of them 
where monocytoid—myeloblast transformation took place, the lysozyme 
activity in the serum and urine was reliably increased (P 0.05). 
The lack of a rise in the lysozyme activity among the patients with acute 
leukosis may be explained by the fact in that them it is a matter of mainly lympho­
cy toid morphological type in which, as already pointed out and according to 
literature data, no changes in the enzyme take place. 
The mean value of a serum lysozyme activity in the 16patiens with myelogenic 
leukosis under study is substantially higher (701.2± 126.0 mcg/ml) in com­
parison with the control group (P>0.05). The latter increase is conditioned by 
the high lysozyme values in four patients (two in the stage of exacerbation, 
and two free of exacerbation phenomena). In the remainder (12 cases) it was 
within normal limits. 
A considerable lysozymuria (reaching up to 2 000 mcg/ml) was recorded 
in two cases of the series, with pronounced renal lesions, most likely due to 
the leukosis process. 
Type of disease 
Chronic Lympha-
tic leukosis £23 Control 
Q *cute leucosis Morbus Hodgttin 
^ ° n S n n i a i m y e l o ~ ^Polycythemia qenous leuKosis ^ 3 vera 
Diag. 1. 
A study of lysozyme (muramidase) activity in the. 7! 
In this group no correlation was established between changes in lysozyme 
and number of leukocytes, duration and type of cytostatic therapy indertaken. 
Among the patients with chronic lymphatic leukosis (14), the mean va ­
lue of serum lysozyme activity is likewise considerably elevated (511.2± 121.7 
mcg/ml) (P 0.05). In four of the patients the activity of serum muramidase 
was very high — exceeding 1 000 m^g/ml, whereas in the other ten it was unal­
tered. Lysozymuria was established in there patients, and in two it was accom­
panied by parallel intensification of the enzyme activity in the serum. Moreo­
ver, we failed to establish a one-way correlation between the changes in acti­
vity of serum lysozyme in the beginning, in remissions and in recurrence of 
the disease, on the one hand, and leukocyte count dynamics, on the other. Pe-
rillie and co-authors claim a reduction of its content (9). 
In the group of malignent lymphoblastoma (15 patients with morbus Hodg-
kin, and 5 with lympho- and reticulosarcoma), the mean value of lyso­
zyme activity in the serum is 282.9±63.6 mcg/ml, and shows no variations 
from the norm. Two patients were with strongly reduced lysozyme activity 
in the serum, reaching 10 mcg/ml. There were two cases in the series with ele­
vated enzyme activity — a woman in I V В clinical stage of morbus Hodgkin 
with heavy renal lesion, and a man with secondary inflammatory process 
subsequent to biopsy. No literature reports were found with a reference to ly­
sozyme studies in malignent lymphoblastomas. 
Of the group with other hematologic diseases, it is worth noting the data 
about the activity of the serum lysozyme in the six cases with polycythemia 
vera where the mean value is the highest-— 1 312.0±400.1 mcg/ml. After 
analysis of the specific values of the enzyme, it was established that the latter 
increase concerns three cases in the initial stage: In the remainder (3 cases) 
which were in the stage of post-treatment remission, the enzyme activity was 
within normal limits. The fact that in these patiens activity enhancement is 
by no means associated with lysozymuria is impressive. Malmquist (6) reports 
a moderate rise of the serum lysozyme in all patients with polycythemia vera. 
No variations in lysozyme activity were detected among the patients 
with myeloma and reticulosis, included in this group. 
The questions concerning clarification of the mechanism of changes in 
muramidase activity have not been fully explained in the literature thus far. 
Presumably, it is a matter of changes conditioned by a variety of causes, na­
mely: nephrotoxic effect of the enzyme, leukemic lesion of the kidneys, en­
hanced production in the leukemic cells or intense cellular decomposition (7) 
8, 9). 
Notwithstanding the fact that our lysozyme study is caried out on a 
comparatively limited number of patients with various nosological entities 
the following preliminary inferences could be reached: 
1. Lysozyme activity in the serum is increased in acute leukosis patients with 
monocytoid-myeloblast transformation of the affection, and in some patients 
with chronic myelogenic and chronic leukosis, and polycythemia vera. 
2. There is no definite correlation between changes in muramidase activity 
and peripheral blood indicators, more particularly, the leukocyte count, and 
the type and duration of cytostatic treatment performed. A rather definite 
correlation between these changes and renal lesions, conditioned by the sys­
temic blood disease, was established in most of the patients. 
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Р Е З Ю М Е 
Обсуждаются результаты исследования лизозимной активности сы­
воротки и мочи у 76 больных с системными заболеваниями крови. Устанав­
ливается повышенная активность энзима у некаторых больных с хрони­
ческими миелолейкозом и лимфолейкозом и истинной полицитемией. Отсут­
ствует определенная зависимость между изменениями в активности лизозима 
и числом лейкоцитов, стадией заболевания, видом и продолжительностью 
нитостатического лечения. 
